Table 1

Ongoing clinical trials for Hydroxychloroquine on COVID-19.

NameIdentifierLocation
  1. Type of study

  2. What to measure

Treatment armActive comparatorPlacebo arm
Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)NCT04307693Sung-Han Kim, Asan Medical Center,
Seoul, South Korea
  1. Multicentre, open-labelled, randomised clinical trial

  2. Viral load

Lopinavir/ritonavir 200 mg/100 mg two tablets by mouth, every 12 hours for 7–10 daysHydroxychloroquine 200 mg two tablets by mouth, every 12 hours for 7–10 daysNo lopinavir/ritonavir and hydroxychloroquine
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)NCT04318444Elizabeth Oelsner, Columbia University,
NY, USA
Parallel assignment (randomised)Hydroxychloroquine
two tablets (400 mg) twice daily on day 1; for days 2–5, they will be instructed to take one tablet (200 mg) twice daily
Two tablets (400 mg) twice daily on day 1; for days 2–5, they will be instructed to take one tablet (200 mg) twice daily
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRANCT04318015National Institute of Respiratory Diseases, Mexico City, Mexico
  1. Triple blinded, randomised controlled trial

  2. Symptomatic covid-19 infection rate

  1. High risk: hydroxychloroquine 200 mg per day for 60 days

  2. Low risk: hydroxychloroquine 200 mg per day for 60 days

  1. High risk: placebo tablet per day for 60 days

  2. Low risk: placebo tablet per day for 60 days

Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)NCT04303507Oxford University,
Oxford, UK
  1. Parallel assignment

  2. Number of symptomatic covid-19 infections

Chloroquine
A loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS CoV-2 Virus (Alliance COVID-19 Brasil II)NCT04321278Hospital Israelita Albert Einstein,
Sao Paulo, Brazil
  1. Parallel assignment

  2. Evaluation of clinical status

Hydroxychloroquine (400 mg 2 times per day, 12/12 hours)+azithromycin (500 mg once a day)Hydroxychloroquine (400 mg 2 times per day, 12/12 hours)
Post-exposure Prophylaxis for SARS-Coronavirus-2NCT04308668University of Minnesota,
Minnesota, USA
  1. Parallel assignment

  2. Incidence of disease

Hydroxychloroquine
200 mg tablet; 800 mg orally once, followed in 6–8 hours by 600 mg, then 600 mg once a day for four consecutive days
Placebo
four placebo tablets once, followed in 6–8 hours by three tablets, then three tablets once a day for four consecutive days